SEC Form 4 · accession 0001209191-15-051491
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Biller
Officer — Chief Scientific Officer
Period of report
Jun 8, 2015
Accepted (ET)
Jun 9, 2015 · 5:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Jun 8, 2015 | S | 5,500 | $121.85 | D | 37,270 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $120.07 to $123.78. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.